Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes

Ribéreau-Gayon, G.; Dumont, Serge; Muller, Christian D.; Jung, Marie‐Louise; Poindron, Philippe; Anton, Robert

doi:10.1016/s0304-3835(96)04401-1

Cited by 65 publications

(30 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Twenty eight cytokine genes were upregulated by VCA (including IL-1α, IL-1β, IL-6, IL-8, IFN-γ, and TNF-α), and five of the genes were upregulated more than 10-fold. The above observations are consistent with the previous studies (Frantz, 1989;Beuth et al, 1994;Riberéau-Gayon et al, 1996) which showed that low non-toxic concentrations of mistletoe lectin can stimulate animal or human macrophages/monocytes. Taken together, these data suggest that a specific network of chemokine genes is activated by VCA, and that this activation is accompanied by a similar activation of the cytokine network.…”

Section: Discussionsupporting

confidence: 93%

“…The lesser secretion of TNF-α might be related to a passive release of cytokines following the secretion of IL-1. These results are consistent with the previous reports on the secretion of cytokines (Hajto et al, 1990;Männel et al, 1991;Hostanska et al, 1995;Riberéau-Gayon et al, 1996;Möckel et al, 1997 Other genes modulated by VCA Among the Fc receptors, the gene coding for FCAR (Fc fragment of IgA receptor) was increased whereas genes coding for FCER1A (Fc fragment of IgE receptor, high affinity I), FCER1G (Fc fragment of IgE receptor, high affinity I, gamma polypeptide), FCGR2C (Fc fragment of IgG receptor, low affinity IIc (CD32)), and FCGRT (Fc fragment of IgG receptor, transporter, alpha) were decreased. Among growth factors, FGF6 (fibroblast growth factor 6), FLT1 (fms-related tyrosine kinase 1), and DTR (diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor)) were increased, and MST1 (macrophage stimulating 1 (hepatocyte growth factor-like)), NRG1 (neuregulin 1), and PDGFD (platelet derived growth factor D) were decreased (Table I and II).…”

Section: Gene Modulation Of Cytokines By Vcasupporting

confidence: 94%

See 1 more Smart Citation

Effect of Korean Mistletoe Lectin on Gene Expression Profile in Human T Lymphocytes: A Microarray Study

Lyu¹,

Park

2010

Biomolecules and Therapeutics

View full text Add to dashboard Cite

-Korean mistletoe has a variety of biological effects, such as immunoadjuvant activities. This study investigates the effects of Korean mistletoe lectin (Viscum album L. var. coloratum agglutinin, VCA) on human T lymphocytes to determine whether VCA acts as an immunomodulator. Purified human T-lymphocytes were cultured with VCA and RNA from each point was analyzed using Affymetrix human genome chips containing 22,500 probe sets which represents more than 18,000 transcripts derived from 14,500 human genes. As a result, there was a striking upregulation of genes coding for chemokines. Seventeen genes out of 50 coding for proteins with chemokine activity were upregulated including CXCL9 and IL-8 which are related to the treatment of cancer. In addition, 28 cytokine genes were upregulated including IL-1, IL-6, IL-8, IFN-γ, and TNF-α. Taken together, the data suggest that Korean mistletoe lectin, in parallel with European mistletoe, has an ability to modulate human T cell function.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Gene Modulation Of Cytokines By Vcasupporting

confidence: 94%

Effect of Korean Mistletoe Lectin on Gene Expression Profile in Human T Lymphocytes: A Microarray Study

Lyu¹,

Park

2010

Biomolecules and Therapeutics

View full text Add to dashboard Cite

show abstract

“…In addition, it has been reported that some bacterial toxins, such as verotoxin, which has the same enzymatic activity and intracellular vesicle trafficking pathway as type 2 RIPs, induce cytokines secretion, and it is considered that the toxin-mediated release of cytokines may have a role in the pathogenesis of the toxin-producing bacteria [28,29]. Mistletoe lectin belonging to type 2 RIP has also been reported to induce TNF-a secretion from human monocytes and T cells [30,31]. Thus, it seems likely that cytotoxic lectins especially type 2 RIPs have an ability to induce multiple cytokines from various cell types as a common biochemical feature.…”

Section: Discussionmentioning

confidence: 99%

Comparative study on modeccin- and phytohemagglutinin (PHA)-induced secretion of cytokines and nitric oxide (NO) in RAW264.7 cells

Kim¹,

Yamasaki²,

Jiang³

et al. 2011

ABBS

View full text Add to dashboard Cite

“…TNF-α and IL-1, and to a variable degree IL-6, were stimulated by mistletoe lectins in cultured mononuclear cells of healthy volunteers. 21 ML-I may enhance cytotoxic NK-cell activity by augmentation of IL-12 secretion. 22 Purified ML-I was shown to increase secretion of TNF-α, IL-1, and IL-6 in vitro from PMNC derived from patient samples.…”

Section: Effects Of Mistletoe On the Immune Systemmentioning

confidence: 99%

Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for the Phase I Study of Botanicals and Botanical-Drug Interactions in Cancer Therapy

Mansky

Grem²,

Wallerstedt³

et al. 2003

Integr Cancer Ther

View full text Add to dashboard Cite

Plant extracts of the European mistletoe (MTE), Viscum album, the most widely used cancer treatment in Germany, have been used in European countries as sole intervention or as adjunct to conventional cancer therapies for more than 80 years. Preclinical data suggest immunostimulatory and cytotoxic effects of MTE. While the clinical efficacy of MTE in cancer is being investigated, toxicity and potential interactions of MTE with standard chemotherapeutic agents are unknown. Gemcitabine is an approved antimetabolite chemotherapeutic agent effective as single agent in patients with solid tumors (ST). The documented metabolism and pharmacokinetics of gemcitabine make this agent well suited for the study of botanical-chemotherapy drug interactions (BDIA) in cancer. Based on reports of altered drug metabolism associated with botanical preparations, research into BDIA has intensified. The phase I, 2-stage, dose-escalation study outlined here will test MTE with gemcitabine as a paradigm for the phase I investigation of botanical-drug combination treatments in patients with advanced ST. The protocol including the following components has been reviewed and approved by the National Cancer Institute Institutional Review Board (IRB), the National Naval Medical Center IRB, and the Navy Clinical Investigation Program (study 02-074): (1) use of a standardized MTE, approved by the Food and Drug Administration for investigational use; (2) independent verification of key MTE components considered biologically active; (3) identification of contaminants and adulterants; (4) pharmacokinetics of gemcitabine and its principal metabolites before and upon exposure to MTE; (5) safety and toxicity data collection; (6) assays of plasma ML antibody production in vivo; and (7) pharmacodynamic studies of the botanical-drug combination.

show abstract

Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes

Cited by 65 publications

References 15 publications

Effect of Korean Mistletoe Lectin on Gene Expression Profile in Human T Lymphocytes: A Microarray Study

Effect of Korean Mistletoe Lectin on Gene Expression Profile in Human T Lymphocytes: A Microarray Study

Comparative study on modeccin- and phytohemagglutinin (PHA)-induced secretion of cytokines and nitric oxide (NO) in RAW264.7 cells

Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for the Phase I Study of Botanicals and Botanical-Drug Interactions in Cancer Therapy

Contact Info

Product

Resources

About